L3VLUP
ProSign in

CNMD · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CNMDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CNMD
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCNMDVRTX
Q3 202010 holders, $208m31 holders, $21.9bn
Q4 20206 holders, $180m30 holders, $18.4bn
Q1 20217 holders, $171m31 holders, $15.4bn
Q2 20214 holders, $185m30 holders, $12.7bn
Q3 20216 holders, $173m35 holders, $10.1bn
Q4 20213 holders, $179m28 holders, $12.4bn
Q1 20226 holders, $233m23 holders, $16.1bn
Q2 20225 holders, $180m25 holders, $18.1bn
Q3 20225 holders, $153m22 holders, $18.4bn
Q4 20225 holders, $209m28 holders, $18.4bn
Q1 20235 holders, $268m26 holders, $21.4bn
Q2 20233 holders, $345m27 holders, $24.7bn
Q3 20237 holders, $301m33 holders, $24.3bn
Q4 20234 holders, $318m32 holders, $28.6bn
Q1 20246 holders, $133m31 holders, $29.8bn
Q2 20244 holders, $134m29 holders, $33.4bn
Q3 20243 holders, $119m27 holders, $33.5bn
Q4 20244 holders, $115m26 holders, $28.5bn
Q1 20253 holders, $109m21 holders, $35.4bn
Q2 20254 holders, $95m21 holders, $32.3bn
Q3 20255 holders, $58m22 holders, $25.9bn
Q4 20254 holders, $43m26 holders, $31.8bn
Q1 20262 holders, $34m25 holders, $31.8bn
Q2 20261 holders, $27m26 holders, $34.6bn
CNMD

Conmed Corp

Holders
4
Reported value
$318m
Buyers
2
Sellers
2

Breadth 0 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CNMD (1)

GAMCO Investors Inc

Only VRTX (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →